Barclays cuts Zealand Pharma stock rating on distant catalysts

Barclays downgraded Zealand Pharma to Equalweight from Overweight and cut its price target to DKK330 from DKK425, citing a limited catalyst runway over the next 12 months and rising obesity-drug competition. The bank retained a $3.0 billion risk-unadjusted peak-sales estimate for petrelintide but reduced survodutide peak sales to $2.3 billion from $3.6 billion amid tolerability concerns. Key petrelintide data are not expected until H2 2026, Q4 2027 and late 2028, while Eli Lilly may deliver pivotal obesity data 6-12 months earlier; Jefferies also recently cut its target to DKK320.

Analysis

ZEAL faces a valuation-duration problem rather than a binary clinical failure: the market must fund several years of R&D and operating spend before its principal wholly owned obesity asset can materially de-risk. In that interval, Lilly’s earlier pivotal readouts can reset both efficacy and discontinuation-rate benchmarks, increasing the probability that ZEAL’s eventual commercial assumptions require lower pricing, narrower positioning, or greater promotional spend. The near-term consequence is likely multiple compression toward cash-adjusted pipeline value rather than a rapid recovery on incremental early-stage updates.

The key second-order risk is that tolerability concerns around the partnered incretin program reduce more than that asset’s standalone NPV: they weaken ZEAL’s strategic value as a combination-therapy platform precisely as large pharma consolidates obesity pipelines around proven, scalable mechanisms. Conversely, a clean cardiovascular or discontinuation profile could restore partnering optionality, making a directional short hazardous around data windows. Cash burn is manageable only if the company retains access to capital on acceptable terms; any accelerated trial plan, partnership revision, or equity issuance would move that debate forward into the next 6-18 months.

Consensus may be too focused on nominal peak-sales estimates and insufficiently focused on time-to-cash-flow. A multi-year catalyst gap warrants a materially higher discount rate for a subscale obesity developer, especially while incumbent leaders can use commercial infrastructure and trial scale to defend share. However, two sell-side downgrades reduce the attractiveness of chasing a short immediately; the better setup is to sell strength into non-thesis-changing updates or use a relative-value structure against LLY.

Key Decisions for Investors

• Initiate a 3-6 month beta-adjusted pair: long LLY / short ZEAL, sized 1:1 on expected volatility rather than dollar notional. The trade captures Lilly’s earlier de-risking and ZEAL’s catalyst vacuum; target 15-20% relative performance, with a stop if ZEAL announces a material upfront partnership, materially improved tolerability data, or a trial acceleration that advances pivotal timing.
• Do not add an outright ZEAL short following downgrade-driven weakness. Set an alert for a 15%+ rebound without new independently verifiable efficacy, discontinuation, or financing information; that is the preferred entry point for the short leg because near-term data-event optionality can produce sharp squeezes.
• For long-only healthcare exposure, retain or add LLY into 6-12 month volatility around obesity readouts rather than rotate into ZEAL on apparent headline valuation. Falsify the relative thesis if Lilly’s pivotal data show clinically meaningful tolerability limitations or if ZEAL demonstrates a differentiated efficacy-to-discontinuation profile sufficient to support premium positioning.
• Monitor ZEAL quarterly for net cash runway, trial-expense guidance, and any change in partner economics. A cash runway falling below roughly 24 months without non-dilutive funding would turn the relative-value thesis into a standalone financing-risk short; confirmation of extended runway or a sizable upfront payment removes that catalyst.